Given that HDAC expression has been reported to be upregulated in medulloblastoma [9], these data suggest that HDAC inhibitors are a new strategy to treat this devastating malignancy, particularly group 3 disease with c-Myc overexpression. The gene discussed is MYC; the disease is medulloblastoma.